Undervalued Pharma Stock

last updated on

Undervalued Pharma Stock

Undervalued Pharma Stock With Huge Potential

Right now, one of the leaders in the weight loss market is Novo Nordisk (NVO). They already have a working product and are also reportedly working on new ones.

However, there is one mid-cap stock that could compete with Novo Nordisk (NVO) in the next few years. We are talking about Viking Therapeutics (VKTX), which is a biotech company.

Viking Therapeutics (Vktx) Is Working On Vk2735

Viking Therapeutics (VKTX) is working to launch its weight loss and management drug in the next few years. The drug they are working on is called VK2735, which will mimic the action of GIP and GLP-1.

So in a sense, the VK2735 drug will work similarly to the Zepbound, another popular weight loss drug from Eli Lilly. The VK2735 has already completed its phase 2 studies and is now in a clinical trial.

As per the reports, the trial of the VK2735 will likely end in August 2027. So, if the trial is a success and the data is positive, then the company will file for regulatory approval by the end of 2027.

So far, studies show that VK2735 led to a 13.1% weight loss, which is really good. In fact, it shows the product is as effective as the famous Zepbound and Wegovy.

Right now, the share price of Viking Therapeutics (VKTX) is at a record low, which is a sign that it is undervalued. Given the success of their new product, there's a solid chance that Viking Therapeutics (VKTX) stock price will reach new highs in the next few years.

But, it's worth mentioning that there is a risk when it comes to buying stocks like Viking Therapeutics (VKTX). On the one hand, if they manage to launch their drug successfully, the stock price will reach new highs.

On the other hand, if the drug fails to hit the market or isn't as effective, it would send the share price lower. So, it is a double-edged sword for those who are thinking of investing in Viking Therapeutics (VKTX) stock.

Trending Stories